Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Shanghai Center of Thyroid Diseases, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Front Endocrinol (Lausanne). 2022 Oct 6;13:993137. doi: 10.3389/fendo.2022.993137. eCollection 2022.
Liver-type fatty acid-binding protein (FABP1) contributes to metabolic disorders. However, the relationship between FABP1 and hyperuricemia remains unknown. We aimed to evaluate the correlation between serum FABP1 and hyperuricemia in patients with obesity before and after laparoscopic sleeve gastrectomy (LSG).
We enrolled 105 patients (47 men and 58 women) with obesity who underwent LSG. They were divided into two groups: normal levels of uric acid (UA) (NUA, n = 44) and high levels of UA (HUA, n = 61) with matching sexes. FABP1 levels and other biochemical parameters were measured at baseline and 3, 6, and 12 months after LSG.
Serum FABP1 levels were significantly higher in the HUA group than in the NUA group (34.76 ± 22.69 ng/mL vs. 25.21 ± 21.68 ng/mL, =0.024). FABP1 was positively correlated with UA (r=0.390, =0.002) in the HUA group. The correlation still existed after adjusting for confounding factors. Preoperative FABP1 levels were risk factors for hyperuricemia at baseline. UA and FABP1 levels decreased at 3, 6, and 12 months postoperatively. FABP1 showed a more significant decrease in the HUA group than in the NUA group at 12 months (27.06 ± 10.98 ng/mL vs. 9.54 ± 6.52 ng/mL, =0.003). Additionally, the change in FABP1 levels positively correlated with changes in UA levels in the HUA group 12 months postoperatively (r=0.512, =0.011).
FABP1 was positively associated with UA and may be a risk factor for hyperuricemia in obesity. FABP1 levels were higher but decreased more after LSG in obese patients with hyperuricemia than in those without hyperuricemia.
肝型脂肪酸结合蛋白（FABP1）参与代谢紊乱。然而，FABP1与高尿酸血症之间的关系尚不清楚。我们旨在评估腹腔镜袖状胃切除术（LSG）前后肥胖患者血清 FABP1 与高尿酸血症之间的相关性。
我们纳入了 105 名接受 LSG 的肥胖患者（47 名男性和 58 名女性）。他们分为两组：尿酸正常组（NUA，n=44）和尿酸升高组（HUA，n=61），性别匹配。在 LSG 前和 3、6、12 个月后测量 FABP1 水平和其他生化参数。
HUA 组血清 FABP1 水平明显高于 NUA 组（34.76±22.69ng/mL 比 25.21±21.68ng/mL，=0.024）。HUA 组 FABP1 与 UA 呈正相关（r=0.390，=0.002）。在调整混杂因素后，相关性仍然存在。术前 FABP1 水平是基线时高尿酸血症的危险因素。UA 和 FABP1 水平在术后 3、6 和 12 个月时下降。在 12 个月时，HUA 组 FABP1 下降更为显著（27.06±10.98ng/mL 比 9.54±6.52ng/mL，=0.003）。此外，HUA 组术后 12 个月 FABP1 水平的变化与 UA 水平的变化呈正相关（r=0.512，=0.011）。
FABP1 与 UA 呈正相关，可能是肥胖患者高尿酸血症的危险因素。与无高尿酸血症的肥胖患者相比，LSG 后高尿酸血症肥胖患者的 FABP1 水平更高，但下降幅度更大。
Zotero 插件